Merck at ASCO 2025: Cancer is a constellation of many rare diseases, one might say
Oncology
Common cancers are being taken and turned into rare sub-groups.
Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria Zazulina, senior vice president, head of development unit oncology at Merck, about the company’s oncology pipeline and portfolio, and the oncological field more broadly.
Watch this and other conversations from ASCO 2025 here.
